Methods of therapy for non-hodgkin's lymphoma

Methods for treating a human with lymphoma using a combination of interleukin-2 and at least one anti-CD20 antibody are provided. These therapeutic agents are administered as two separate pharmaceutical compositions, one containing IL-2, the other containing at least one anti-CD20 antibody, according to a dosing regimen. Administering of these two therapeutic agents together potentiates the effectiveness of either agent alone, resulting in a positive therapeutic response that is improved with respect to that observed with either agent alone. The therapeutic effects of these agents can be achieved using lower dosages of IL-2, thereby lessening the toxicity of prolonged IL-2 administration and the potential for tumor escape.